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Background: Treatment Resistant Schizophrenia (TRS) patients show more severe impairments in community functioning compared to Antipsychotic Responder Schizophrenia (ARS) patients. The scope of this work was to assess whether TRS patients suffer from more severe alterations in functional capacity, i.e. the baseline potential of a patient to function in the community, and whether factors affecting functional capacity differ between TRS and ARS patients. Methods: 60 out of 182 eligible patients were included. A multistep diagnostic procedure to separate TRS from ARS was then used. Patients were administered a range of assessment tools including (but not limited to): the PANSS; cognitive performances tests; the Specific Level of Functioning (SLOF); the Neurological Evaluation Scale (NES); the UCSD PerformanceBased Skills Assessment (UPSA) extended version. Univariate and multivariate statistics were performed. Significance was set at p<.05. Results: After controlling for covariates, no significant differences in both total and subscales UPSA scores were found between TRS and ARS patients. However, TRS patients constantly scored lower than ARS patients.
Stepwise regression was used to determine predictors of UPSA score. The first group encompassed clinical variables. In the whole sample, the final significant model, F(2,57)=18.848, p<.0005, adjusted R2=.37, included: PANSS negative subscale score and NES score. In TRS patients, the final significant model, F(3,24)=16.552, p<.0005, adjusted R2=.63, included PANSS negative scale score, education years, and NES score. In ARS patients, no significant models were found. The second group included cognitive performance variables. In the whole sample, the final significant model, F(2,57)=7.64, p=.001, adjusted R2=.18, included Problem Solving and Verbal Memory. In TRS patients, the final significant model included Problem Solving and VisuoSpatial Memory. In ARS patients, the final significant model included Verbal Memory only. The third group included psychosocial variables. In the whole sample, the final significant model, F(1,58)=18.82, p<.0005, adjusted R2=.23, included SLOF Area5 score only. In TRS patients the final significant model included SLOF Area1 score only, while in ARS patients, no significant models were found. By hierarchical multiple regressions, NES score was found to be predictive of the highest UPSA score variance ratio among schizophrenia patients. The addition of PANSS Negative scale score and Problem Solving (in this order) led to a statistically significant increase in R2. No further models were found to add significant increase in R2. In TRS patients, PANSS Negative scale score was the variable that explained the most variance in UPSA score. The addition of Problem Solving and education years (in this order) led to a statistically significant increase in R2. No further models were found to add significant increase in R2, although NES score showed a trend toward significance. At last, we performed a path analysis to evaluate the type (direct or indirect) and the direction of relationships among these variables and UPSA score. The only variables that were in direct relationship with UPSA score were PANSS Negative Scale score and Problem Solving. SLOF Area5 was in indirect relationship with UPSA score by PANSS Negative Scale score, while NES score relationship with UPSA score was mediated by Problem Solving. Discussion: Our study demonstrated that negative symptoms, altered cognitive performances, and more severe neurological soft signs were the major factors influencing functional capacity in schizophrenia patients. These factors were more relevant in TRS than in ARS patients. Background: Clinical and preclinical studies suggest that selective activators of the muscarinic M4 receptor have exciting potential as a novel approach for treatment of schizophrenia. M4 reduces striatal dopamine (DA) though release of endocannabinoids (eCB), providing a mechanism for local effects on DA signaling in the striatum. M4 signals through Gαi/o and does not couple to Gαq/11 or induce calcium (Ca++) mobilization. This raises the possibility that M4-induced eCB release and inhibition of DA release may require co-activation of another receptor that activates Gαq/11. If so, this receptor could provide a novel target that may be more proximal to inhibition of DA release. Interestingly, the group 1 metabotropic glutamate (mGlu) receptors (mGlu1 and Glu5), couple to Gαq/11 and activate eCB signaling in multiple brain regions.
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Methods:
We tested the hypothesis that M4-induced reductions in DA release and subsequent antipsychotic-effect requires co-activation of group 1 mGlu receptors. The effect of M4 activation on electrically-evoked DA release in striatal slices was assessed using fast-scan cyclic voltammetry (FSCV) in the absence or presence of selective negative allosteric modulators (NAMs) of group 1 mGlu receptor subtypes. To evaluate the potential role of mGlu1, we determined the effects of a selective mGlu1 positive allosteric modulators (PAMs) on striatal DA release and antipsychotic-like activity in rodent models that are dependent on increased DA transmission. Since reductions in DA signaling, including D1 signaling have been implicated in reduced motivation, we also determined the effects of an mGlu1 PAM, M4 PAM, and the typical antipsychotic haloperidol on motivational responding in a progressive ratio (PR) schedule.
Results:
We now present exciting new data in which we found that activation of mGlu1 through application of exogenous agonists or selective stimulation of thalamostriatal afferents induces a reduction of striatal DA release and that selective mGlu1 PAMs have robust antipsychotic-like effects in rodent models. Interestingly, our studies also suggest that mGlu1 activation is required for M4 PAM-induced inhibition of DA release and antipsychotic-like effects. However, in contrast to available antipsychotic agents, the present results and previous studies suggest that mGlu1 and M4 PAMs reduce DA signaling through local release of an eCB from striatal SPNs and activation of CB2 receptors on neighboring DA terminals to reduce DA release. While these studies suggest that the effects of M4 PAMs on DA release require activation of mGlu1, we have also found that these targets have important differences. Most notably, M4 PAMs also directly inhibits D1 signaling in D1-SPN terminals in the substatnia nigra pars reticulata (SNr). Unlike M4, mGlu1 does not directly inhibit DA D1 receptor signaling and does not induce behavioral changes that could be associated with negative symptoms. Discussion: Our findings are especially interesting in light of recent findings that multiple loss of function single nucleotide polymorphisms (SNPs) in the human gene encoding mGlu1 (GRM1) are associated with schizophrenia, and points to GRM1/mGlu1 as a gene within the "druggable genome" that could be targeted for treatment of schizophrenia. Recent clinical imaging studies suggesting that symptoms in schizophrenia patients are associated with selective increases in striatal DA signaling and while extrastriatal regions display hypo-dopaminergic function; thus, mGlu1 and M4 PAMs may provide a mechanism for selective inhibition of DA release in striatal regions that are important for antipsychotic efficacy, without further disruptions in extrastriatal DA signaling.
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